

# CITATION REPORT

List of articles citing

## Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial

DOI: 10.1001/jama.2015.9243

JAMA - Journal of the American Medical Association,  
2015, 314, 677-686.

**Source:** <https://exaly.com/paper-pdf/62611809/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
475	Scientific surgery. <b>2015</b> , 102, 1733-1733		
474	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1268-76	7	7 <sup>1</sup>
473	Vascular complications in glioma patients. <b>2016</b> , 134, 251-66		6
472	Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. <b>2016</b> , 7, 68527-68545		24
471	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. <b>2016</b> , 38, 365-377		2
470	Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate. <b>2016</b> , 2016, 6413541		1
469	Thromboembolic Disease in Cancer. <b>2016</b> , 213-225		
468	Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. <b>2016</b> , 10, 2041-6		9
467	Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. <b>2016</b> , 10, 2677-9		
466	Deep vein thrombosis and pulmonary embolism. <b>2016</b> , 388, 3060-3073		34 <sup>0</sup>
465	Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. <i>Thrombosis Research</i> , <b>2016</b> , 144, 85-92	8.2	25
464	Embolie pulmonaire et anticoagulants. <b>2016</b> , 8, S18-S23		
463	Thrombosis in the setting of cancer. <b>2016</b> , 2016, 196-205		27
462	Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. <b>2016</b> , 2016, 206-207		4
461	Maladie veineuse thromboembolique et cancer. <b>2016</b> , 8, 489-496		
460	Cancer-Associated Venous Thromboembolism. <b>2016</b> , 18, 23		8
459	Venous thromboembolism in cancer patients: risk assessment, prevention and management. <b>2016</b> , 12, 221-35		2

458	Cancer-associated thrombosis. <b>2016</b> , 62, 121-58		37
457	Update of thrombosis in multiple myeloma. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S76-80	8.2	31
456	Management of recurrent venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S128-31	8.2	8
455	LMWH in cancer patients with renal impairment - better than warfarin?. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S160-4	8.2	8
454	Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S93-8	8.2	17
453	The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S154-9	8.2	17
452	Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2016</b> , 22, 617-26	3.3	2
451	The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. <i>Thrombosis Research</i> , <b>2016</b> , 144, 21-6	8.2	16
450	Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. <i>Thrombosis Research</i> , <b>2016</b> , 147, 102-103	8.2	7
449	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , <b>2016</b> , 17, e452-e466	21.7	252
448	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <b>2016</b> , 17, 2033-47		4
447	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <b>2016</b> , 3, e379-87		93
446	Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 2107-2113	15.4	43
445	The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. <b>2016</b> , 11, 1031-1035		11
444	A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. <b>2016</b> , 42, 494-504		24
443	Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, S24-S32	7	16
442	Direkte orale Antikoagulanzen bei Tumorpatienten Eine Alternative?. <b>2016</b> , 11, 8-14		
441	Management of venous thromboembolism: an update. <b>2016</b> , 14, 23		25

440	Thromboembolic disease and breathlessness. <b>2016</b> , 10, 249-55		3
439	[Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications]. <b>2016</b> , 41, 197-204		2
438	Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. <i>Thrombosis Research</i> , <b>2016</b> , 144, 12-20	8.2	4
437	Drug Treatment of Venous Thromboembolism in the Elderly. <b>2016</b> , 33, 475-90		6
436	Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center. <i>Thrombosis Research</i> , <b>2016</b> , 142, 52-6	8.2	12
435	Kein Nutzen einer zusätzlichen CT-Diagnostik zur Tumorsuche bei Patienten mit unprovoked Thrombose. <b>2016</b> , 13, 198-199		
434	Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. <b>2016</b> , 41, 206-32		210
433	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <b>2016</b> , 41, 81-91		138
432	Management of Pulmonary Embolism: An Update. <b>2016</b> , 67, 976-990		182
431	[Venous thrombosis and pulmonary embolism : Updated S2 guidelines on diagnostics and therapy]. <b>2016</b> , 65, 212-20		0
430	Treating patients with cancer and acute venous thromboembolism. <b>2016</b> , 17, 535-43		2
429	Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy. <b>2016</b> , 76, 331-41		5
428	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <b>2016</b> , 149, 315-352		3090
427	Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 662-669	15.4	23
426	Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. <i>Thrombosis Research</i> , <b>2017</b> , 150, 86-89	8.2	32
425	Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism?. <b>2017</b> , 49,		4
424	Pulmonary Embolism. <b>2017</b> , 6, 244-260		1
423	Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria. <b>2017</b> , 25, 2093-2102		5

422	Management of Cancer-Associated Venous Thromboembolism in the Emergency Department. <b>2017</b> , 69, 768-776			1
421	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. <b>2017</b> , 129, 3285-3293			27
420	Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. <b>2017</b> , 129, 3379-3385			46
419	Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians. <b>2017</b> , 12, 437-443			3
418	Pharmacological management of pulmonary embolism. <b>2017</b> , 18, 79-93			3
417	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. <b>2017</b> , 2, e000188			23
416	Current challenges and future prospects in oral anticoagulant therapy. <b>2017</b> , 178, 838-851			21
415	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <b>2017</b> , 120, 206-218			10
414	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study. <i>Thrombosis Research</i> , <b>2017</b> , 153, 57-64	8.2		28
413	Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. <i>Thrombosis Research</i> , <b>2017</b> , 150, 53-58	8.2		8
412	Advances in managing and preventing thromboembolic disease in cancer patients. <b>2017</b> , 11, 347-354			5
411	Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. <b>2017</b> , 44, 442-447			22
410	Thromboembolic Disorders as a Consequence of Cancer. <b>2017</b> , 57-74			
409	Prolonged anticoagulant treatment in patients with cancer: Where do we stand?. <i>Thrombosis Research</i> , <b>2017</b> , 158, 152-153	8.2		2
408	Parenteral anticoagulation in ambulatory patients with cancer. <i>The Cochrane Library</i> , <b>2017</b> , 9, CD006652	5.2		22
407	Extended anticoagulation in venous thromboembolism disease. In favour. <b>2017</b> , 217, 359-364			
406	Extended anticoagulation in venous thromboembolism disease. In favor. <b>2017</b> , 217, 359-364			0
405	Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. <i>Thrombosis Research</i> , <b>2017</b> , 157, 90-96	8.2		61

404	When can we stop anticoagulation in patients with cancer-associated thrombosis?. <b>2017</b> , 130, 2484-2490		14
403	Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 1757-1763	15.4	24
402	Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. <b>2017</b> , 35, 490-499		7
401	Management of incidental pulmonary embolism. <b>2017</b> , 49,		24
400	Inferior vena cava filters. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 3-12	15.4	51
399	Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice. <b>2017</b> , 25, 59-66		5
398	Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. <b>2017</b> , 43, 233-240		12
397	Controversies in the management of cancer-associated thrombosis. <b>2017</b> , 10, 15-22		15
396	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <b>2017</b> , 130, 337-347		45
395	Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 74-79	15.4	30
394	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , <b>2017</b> , 12, CD006466	5.2	13
393	Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1952-1961	7	49
392	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 219-230	7	208
391	Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1192-1198	7	15
390	Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2163-2167	7	1
389	Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?. <i>Hamostaseologie</i> , <b>2017</b> , 37, 241-255	1.9	7
388	When can we stop anticoagulation in patients with cancer-associated thrombosis?. <b>2017</b> , 2017, 128-135		11
387	Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. <b>2017</b> , 1, 707-714		14

386	Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins. <b>2017</b> , 4, 142		9
385	Deep Vein Thrombosis of the Upper Extremity. <b>2017</b> , 114, 244-249		30
384	Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. <b>2017</b> , 9, 65-73		3
383	Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. <b>2017</b> , 13, 720-727		7
382	Reply to R. Fonseca et al. <b>2017</b> , 35, 2218-2219		
381	Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <b>2017</b> , 35, 1078-1085		41
380	Tissue Factor: Catch Me If You Can!. <b>2017</b> , 35, 1128-1130		8
379	Thrombosis in cancer patients: etiology, incidence, and management. <b>2017</b> , 7, S178-S185		36
378	3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. <b>2017</b> , 109, 1-104		11
377	Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 124, 41-50	7	20
376	Anticoagulation in Venous Thromboembolism. <b>2018</b> , 297-323		
375	Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 1069-1077	15.4	17
374	Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. <b>2018</b> , 101, 136		23
373	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <b>2018</b> , 23, 822-839		13
372	Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016. <b>2018</b> , 36, 73-91		
371	Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. <b>2018</b> , 93, 664-671		54
370	How Fragile Are Clinical Trial Outcomes That Support the CHEST Clinical Practice Guidelines for VTE?. <b>2018</b> , 154, 512-520		14
369	The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis. <b>2018</b> , 34, 530-534		14

368	Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. <b>2018</b> , 7,		14
367	Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. <b>2018</b> , 45, 377-385		5
366	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , <b>2018</b> , 1, CD006649	5.2	18
365	[Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms]. <b>2018</b> , 43, 34-42		2
364	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. <b>2018</b> , 131, 430-437		11
363	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <i>Thrombosis Research</i> , <b>2018</b> , 163, 41-46	8.2	27
362	Overview of VTE treatment in cancer according to clinical guidelines. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S162-S167	8.2	10
361	Managing thrombosis in cancer patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 429-438	5.1	29
360	Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database. <b>2018</b> , 2, e158-e166		2
359	Management of recurrent venous thromboembolism in patients with cancer: A review. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S172-S177	8.2	12
358	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S168-S171	8.2	0
357	Are new anticoagulants a safe and reasonable alternative to low molecular heparins?. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S157-S161	8.2	3
356	Thrombosis in pediatric patients with leukemia. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S94-S97	8.2	13
355	Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. <b>2018</b> , 38, 610-618		6
354	[Cancer and venous thromboembolism recurrence: The keys for an optimal management]. <i>Bulletin Du Cancer</i> , <b>2018</b> , 105, 508-516	2.4	1
353	Novel Mechanism of Cancer Thrombosis Induced by Microvesicles. <b>2018</b> , 38, 692-694		1
352	Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism. <i>HemaSphere</i> , <b>2018</b> , 2, e19	0.3	3
351	Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?. <b>2018</b> , 12, 387-402		1

350	A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). <i>Thrombosis Research</i> , <b>2018</b> , 162, 88-92	8.2	43
349	Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 226-234	3.3	5
348	Epidemiology of the post-thrombotic syndrome. <i>Thrombosis Research</i> , <b>2018</b> , 164, 100-109	8.2	52
347	Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment. <b>2018</b> , 32, 144-158		9
346	Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. <b>2018</b> , 52, 257-262		3
345	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <b>2018</b> , 378, 615-624		806
344	Anticoagulation for Proximal Deep Vein Thrombosis. <b>2018</b> , 299-313		0
343	The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines. <b>2018</b> , 26, 711-720		5
342	The Role of Tinzaparin in Oncology. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 697-707	3.3	10
341	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). <b>2018</b> , 36, 2017-2023		607
340	Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. <i>Current Oncology</i> , <b>2018</b> , 25, 329-337	2.8	38
339	Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. <b>2018</b> , 2, e373-e386		8
338	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <b>2018</b> , 2, 37-49		1
337	Thromboprophylaxis after Hospitalization for Medical Illness. <b>2018</b> , 379, 2280		0
336	Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 132, 76-88	7	12
335	[Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018?]. <i>JMV-Journal De Medecine Vasculaire</i> , <b>2018</b> , 43, 293-301	0.6	1
334	Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 132, 169-179	7	29
333	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 209S-216S	3.3	2

332	Management of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 2391-2396	15.4	7
331	Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 1825-1875	3.3	24
330	Thrombosis and Bleeding in Cancer Patients. <b>2018</b> , 303-318		0
329	Update on extended treatment for venous thromboembolism. <b>2018</b> , 50, 666-674		14
328	Anticoagulants in frail patients. Seven situations at risk. <i>JMV-Journal De Medecine Vasculaire</i> , <b>2018</b> , 43, 302-309	0.6	1
327	D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. <b>2018</b> , 119, 915-921		22
326	The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways. <b>2018</b> , 23,		7
325	COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <b>2018</b> , 16, 21		13
324	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. <i>Thrombosis Research</i> , <b>2018</b> , 170, 175-180	8.2	21
323	How I diagnose and treat venous thromboembolism in sickle cell disease. <b>2018</b> , 132, 1761-1769		20
322	Factors to Consider Regarding the Need for Inferior Vena Cava Filters. <b>2018</b> , 60, 622-628		3
321	Anticoagulation for people with cancer and central venous catheters. <i>The Cochrane Library</i> , <b>2018</b> , 6, CD096468		20
320	The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy. <b>2018</b> , 26, 670-682		1
319	Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. <b>2018</b> , 8, 64		27
318	Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. <b>2018</b> , 8, 65		24
317	Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. <b>2018</b> , 19, 1177-1185		10
316	[What role for the direct oral anticoagulants in oncology?]. <i>Bulletin Du Cancer</i> , <b>2018</b> , 105, 631-633	2.4	
315	Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 1891-1894	15.4	189

314	Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 130, 44-50	7	5
313	Management and treatment of deep vein thrombosis in special populations. <b>2018</b> , 11, 685-695		10
312	Anticoagulation for perioperative thromboprophylaxis in people with cancer. <i>The Cochrane Library</i> , <b>2018</b> , 7, CD009447	5.2	7
311	Acute Pulmonary Embolism in Emergency Department Patients Despite Therapeutic Anticoagulation. <b>2018</b> , 19, 510-516		7
310	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. <i>Cancers</i> , <b>2018</b> , 10,	6.6	28
309	Venous Thromboembolism and Cancer. <b>2018</b> , 20, 89		13
308	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <b>2018</b> , 2, e210-e217		4
307	Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin. <b>2018</b> , 13, 1089-1091		4
306	Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , <b>2018</b> , 6, CD006650	5.2	41
305	Venous thromboembolism incidence in hematologic malignancies. <b>2019</b> , 33, 24-32		29
304	Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. <b>2019</b> , 94, 1185-1192		25
303	Biomarkers of Cancer-Associated Thromboembolism. <b>2019</b> , 179, 69-85		5
302	Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. <b>2019</b> , 179, 103-115		6
301	Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database. <b>2019</b> , 38, 173-184		4
300	Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1590-1607	15.4	19
299	Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. <b>2019</b> , 8,		9
298	The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism. <i>Thrombosis Research</i> , <b>2019</b> , 181, 59-63	8.2	3
297	Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies. <b>2019</b> , 10, 773		11

296	Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer. <b>2019</b> , 153, 122-125		
295	Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. <b>2019</b> , 15, 175-186		14
294	Ischemic lesions in all territories as a marker of malignant hypercoagulability. <b>2019</b> , 7, 1312-1315		
293	Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. <b>2019</b> , 8, e013395		2
292	Oncologic Emergencies: Too Much Clotting-Venous Thromboembolism in Malignancy. <b>2019</b> , 57, 825-835		2
291	Thromboembolic disease in palliative and end-of-life care: A narrative review. <i>Thrombosis Research</i> , <b>2019</b> , 175, 84-89	8.2	7
290	Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. <i>Cancers</i> , <b>2019</b> , 11,	6.6	5
289	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). <b>2019</b> , 54,		413
288	Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI. <b>2019</b> , 3, e309-e315		6
287	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , <b>2019</b> , 180, 37-42	8.2	8
286	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619856433	3.3	2
285	Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2019</b> , 3, 349-356	5.1	16
284	Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. <i>Journal of Medical Economics</i> , <b>2019</b> , 22, 1134-1140	2.4	7
283	Treatment of venous thromboembolism with tinzaparin in oncological patients. <b>2019</b> , 110, 251-258		2
282	Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. <b>2019</b> , 57, 685-701		13
281	High incidence of venous thromboembolism recurrence in patients with sickle cell disease. <b>2019</b> , 94, 862-870		9
280	Thromboembolism and Bleeding. <b>2019</b> , 1297-1316		
279	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. <b>2019</b> , 17, 6		10

278	Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. <b>2019</b> , 14, e0213940		31
277	Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. <b>2019</b> , 290, 144-149		9
276	Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <b>2019</b> , 73, 1336-1349		56
275	Cancer-associated thrombosis: the when, how and why. <b>2019</b> , 28,		53
274	Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. <b>2019</b> , 47, 495-504		11
273	Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. <b>2019</b> , 30, 897-907		46
272	Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. <b>2019</b> , 18, 313-320		3
271	Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. <b>2019</b> , 116, 31-38		5
270	Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 45	6.3	14
269	Venous thromboembolism: A clinician update. <b>2019</b> , 24, 122-131		12
268	Duration of anticoagulant therapy and VTE recurrence in patients with cancer. <b>2019</b> , 27, 3833-3840		5
267	Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. <i>Thrombosis Research</i> , <b>2019</b> , 177, 33-41	8.2	10
266	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <b>2019</b> , 139, e579-e602		86
265	How I treat cancer-associated thrombosis. <b>2020</b> , 5, e000610		13
264	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <b>2019</b> , 3, 3770-3779		23
263	The impact of venous thromboembolism on the outcomes of patients with cervical carcinoma, a retrospective analysis at a single institution. <b>2019</b> , 11, 25-30		0
262	Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. <b>2019</b> , 94, 2444-2454		17
261	Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. <b>2019</b> , 21, 70		1

260	Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: A single-center study. <b>2019</b> , 98, e16514		2
259	Comparative outcomes of catheter-directed thrombolysis plus rivaroxaban vs rivaroxaban alone in patients with acute iliofemoral deep vein thrombosis. <b>2019</b> , 82, 902-908		
258	The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. <b>2019</b> , 94, E58-E61		8
257	Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update. <b>2019</b> , 47, 409-419		6
256	Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect. <i>Cancers</i> , <b>2019</b> , 11,	6.6	10
255	Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
254	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. <b>2019</b> , 59, 27-33		18
253	Use of Vena Cava Filters and Venous Access Devices. <b>2019</b> , 594-635		
252	Thrombosis and Cancer. <b>2019</b> , 430-447		
251	Parenteral Antithrombotic Agents. <b>2019</b> , 529-539		
250	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <b>2019</b> , 14, 21-38		8
249	Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. <b>2019</b> , 25, 52-59		10
248	Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness. <b>2019</b> , 25, 68-75		3
247	Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. <b>2019</b> , 25, 362-368		9
246	Assessment of bleeding incidences associated with rivaroxaban therapy in adults with solid tumors. <b>2019</b> , 25, 192-197		
245	ClotAssist: A program to treat cancer-associated thrombosis in an outpatient pharmacy setting. <b>2019</b> , 25, 818-823		4
244	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2019</b> , 173, 158-163	8.2	149
243	A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience. <b>2019</b> , 25, 793-800		11

242	First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction. <b>2020</b> , 33, 356-363		
241	Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. <b>2020</b> , 22, 616-620		1
240	Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 411-421	15.4	194
239	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <b>2020</b> , 41, 543-603		1043
238	Cancer-associated thrombosis: Where do we stand?. <b>2020</b> , 3, e73		2
237	Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications. <b>2020</b> , 20, 223-228		7
236	Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials. <b>2020</b> , 50, 305-310		7
235	Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model. <b>2020</b> , 28, 3755-3761		3
234	Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis. <b>2020</b> , 523-543.e7		1
233	Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 651-659	15.4	13
232	Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine. <b>2020</b> , 36, 280-287		2
231	Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil. <i>Thrombosis Research</i> , <b>2020</b> , 196, 4-10	8.2	1
230	Evolving Treatment Options for Cancer-Related Venous Thromboembolism. <b>2020</b> , 2, 441-442		1
229	Off-Label Medicines Use: Complex Problem of Modern Clinical Practice. <b>2020</b> , 16, 324-334		
228	Therapie und Prophylaxe der tumor-assoziierten venösen Thromboembolie. <b>2020</b> , 23, 25-30		
227	Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. <b>2020</b> , 24, 653		38
226	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). <i>JMV-Journal De Medecine Vasculaire</i> , <b>2020</b> , 45, 6S17-6S23	0.6	2
225	Cancer-associated thrombosis in pediatric patients. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S22-S25	8.2	3

224	Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S68-S73	8.2	3
223	[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism]. <b>2020</b> , 41, 575-577		
222	Thrombosis in hematological malignancies: mechanisms and implications. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S58-S62	8.2	5
221	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S123-S127	8.2	0
220	Venous thromboembolism in palliative care patients: what do we know?. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S128-S132	8.2	0
219	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <b>2020</b> , 133, 175-178		3
218	Tinzaparin for venous thromboembolism in patients with renal impairment - a single-centre, prospective pilot study. <b>2020</b> ,		2
217	Management of Cancer-Associated Thrombosis. <b>2020</b> , 22, 1		1
216	Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1765-1776	27.4	23
215	Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. <b>2020</b> , 76, 2142-2154		8
214	Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 3267-3279	15.4	1
213	Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. <i>Thrombosis Research</i> , <b>2020</b> , 196, 238-244	8.2	3
212	Postoperative statin treatment may be associated with improved mortality in patients with myocardial injury after noncardiac surgery. <b>2020</b> , 10, 11616		3
211	Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. <b>2020</b> , 1, 448-456		1
210	Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620954282	3.3	7
209	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. <b>2020</b> , 18, 791-800		2
208	Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. <b>2020</b> , 10, 18945		4
207	[Treatment recommendations in cardio-oncology: where are we?]. <b>2020</b> , 61, 1125-1131		0

206	Tumorassoziierte venöse Thromboembolie [Pathogenese, Diagnose, Prävention und Therapie. <b>2020</b> , 15, 448-455		
205	Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 152, 103005	7	3
204	Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
203	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <b>2020</b> , 136, 1433-1441		45
202	Prevention and treatment of venous thromboembolism in cancer patients. <b>2020</b> , 45, 652-658		1
201	Treatment of deep vein thrombosis of the lower extremities. <b>2020</b> , 220, 57-57		
200	Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. <b>2020</b> , 9, e017559		101
199	Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. <i>Thrombosis Research</i> , <b>2020</b> , 188, 106-114	8.2	9
198	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <b>2020</b> , 382, 1599-1607		320
197	Massive Fatal Pulmonary Embolism While on Therapeutic Heparin Drip. <b>2020</b> , 8, 2324709620914787		0
196	Rivaroxaban Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. <b>2020</b> , 34, 829-837		4
195	Comparison of acute and chronic myocardial injury in noncardiac surgical patients. <b>2020</b> , 15, e0234776		4
194	Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism. <i>Hamostaseologie</i> , <b>2020</b> , 40, 655-661	1.9	0
193	Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
192	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). <i>JMV-Journal De Medecine Vasculaire</i> , <b>2020</b> , 45, 28-40	0.6	3
191	DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. <b>2020</b> , 50, 661-667		11
190	SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). <b>2020</b> , 22, 171-186		10
189	Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 905-915	15.4	27

188	Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. <i>Thrombosis Research</i> , <b>2020</b> , 187, 125-130	8.2	0
187	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. <b>2020</b> , 25, 210-217		2
186	Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. <b>2020</b> , 20, 53		1
185	Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. <b>2020</b> , 77, 86-96		2
184	Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology. <b>2020</b> , 99, e19679		
183	Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
182	Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?. <b>2020</b> , 21, 43		1
181	Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 532-549	5.1	5
180	Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620918290 <sup>3,3</sup>		5
179	Early detection of the existence or absence of the treatment effect: A cumulative meta-analysis. <b>2020</b> , 124, 24-33		2
178	Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. <b>2021</b> , 51, 102-111		1
177	Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. <b>2021</b> , 160, 312-321		4
176	Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <b>2021</b> , 26, e8-e16		10
175	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <b>2021</b> , 127, 938-945		5
174	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <b>2021</b> , 32, 171-182		17
173	Deep vein thrombosis and brain metastases. Case report and systematic review. <i>Thrombosis Research</i> , <b>2021</b> , 197, 195-201	8.2	1
172	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. <b>2021</b> , 77, 629-658		45
171	An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. <b>2021</b> , 22, 583-594		1

170	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103125	7	1
169	Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 383-395	7	9
168	Left ventricular thrombi in malignancy: A therapeutic dilemma. <b>2021</b> , 50, 231		
167	Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 212-220	15.4	3
166	Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer. <b>2021</b> , 23, 697-708		
165	[What duration of anticoagulant treatment for PE/proximal DVT?]. <b>2021</b> , 38 Suppl 1, e99-e112		
164	[What are the special features of the treatment of venous thromboembolic disease in the course of cancer?]. <b>2021</b> , 38 Suppl 1, e138-e144		
163	Anticoagulation and Antiplatelet Guidelines. <b>2021</b> , 201-223		
162	Review of Medical Therapies for the Management of Pulmonary Embolism. <b>2021</b> , 57,		4
161	Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. <i>Hamostaseologie</i> , <b>2021</b> , 41, 48-57	1.9	6
160	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. <b>2021</b> , 52, 214-223		0
159	Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies?. <b>2021</b> , 193, 194-197		1
158	DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021). <b>2021</b> , 44-77		3
157	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <b>2021</b> , 5, 927-974		96
156	Intraoperative blood loss may be associated with myocardial injury after non-cardiac surgery. <b>2021</b> , 16, e0241114		4
155	Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. <b>2021</b> , 5, 1050-1058		0
154	Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , <b>2021</b> , 56, 6-16	1.4	0
153	Current status of treatment of cancer-associated venous thromboembolism. <b>2021</b> , 19, 21		6

152	Associations Between Preoperative Glucose and Hemoglobin A1c Level and Myocardial Injury After Noncardiac Surgery. <b>2021</b> , 10, e019216		5
151	Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism - A Retrospective Observational Study. <b>2021</b> ,		1
150	Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer. <b>2021</b> , 33, 1123-1134		1
149	Challenges and Advances in Managing Thrombocytopenic Cancer Patients. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	6
148	Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. <b>2021</b> ,		1
147	[What are the indications for a caval filter?]. <b>2021</b> , 38 Suppl 1, e69-e73		0
146	[Which aetiological investigations to undertake during the progress of PE/DVT?]. <b>2021</b> , 38 Suppl 1, e90-e98		
145	The Effectiveness of Long-term Use of Low-Molecular-Weight Heparin on Venous Thromboembolism After Sleeve Gastrectomy in Rats.		
144	[Treatment of cancer associated thrombosis. 2019 update of the French guidelines]. <b>2021</b> , 38, 427-437		1
143	Venous and Arterial Thromboembolism in Patients With Cancer: : State-of-the-Art Review. <b>2021</b> , 3, 173-190		10
142	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <b>2021</b> , 12, 684638		9
141	Burden of venous thromboembolism in patients with pancreatic cancer. <b>2021</b> , 27, 2325-2340		3
140	Incidence and risk factors for venous thromboembolism in a cohort of Taiwanese patients with lung, gastric, pancreatic cancers or lymphoma. <b>2021</b> , 121, 360-360		0
139	Prognosis of Myocardial Injury After Non-Cardiac Surgery in Adults Aged Younger Than 45 Years. <b>2021</b> , 85, 2081-2088		1
138	Cancer-Associated Thrombosis: A New Light on an Old Story. <b>2021</b> , 9,		5
137	Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism. <b>2021</b> , 7, 27-38		
136	Cancer and Thrombosis: New Treatments, New Challenges. <b>2021</b> , 9,		1
135	Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. <i>Thrombosis Research</i> , <b>2021</b> , 202, 128-133	8.2	2

134	TEMPORARY REMOVAL: Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. <b>2021,</b>			1
133	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <b>2021,</b> 5, e376-e386			7
132	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <b>2021,</b> 160, e545-e608			48
131	Balancing Risk of Thromboembolism and Bleeding in Patients with Cancer: Selecting Anticoagulant Therapy Based on Recent Clinical Trials.			
130	Association between cardiologist evaluation and mortality in myocardial injury after non-cardiac surgery. <b>2021,</b>			2
129	Invited Review: Optimal Management of Upper Extremity DVT: Is Venous Thoracic Outlet Syndrome Underrecognized?. <b>2021,</b>			0
128	Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. <i>Journal of Thrombosis and Haemostasis,</i> <b>2021,</b> 19, 2825-2834	15.4		2
127	Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data. <b>2021,</b> 1-7			2
126	A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism. <b>2021,</b> 61, e26-e38			
125	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis,</i> <b>2021,</b>	7		3
124	Venous thromboembolism: Recent advancement and future perspective. <b>2022,</b> 79, 79-89			3
123	How I treat and prevent venous thrombotic complications in patients with lymphoma. <b>2021,</b>			1
122	Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis,</i> <b>2021,</b> 27, 1076029620979592	3.3		1
121	Clinical controversies in the treatment of cancer-associated venous thromboembolism. <b>2021,</b> 27, 939-953			0
120	Elevated high-sensitivity C-reactive protein concentrations may be associated with increased postdischarge mortality in patients with myocardial injury after noncardiac surgery: A retrospective observational study. <b>2021,</b> 38, S33-S40			2
119	Pre-operative anaemia and myocardial injury after noncardiac surgery: A retrospective study. <b>2021,</b> 38, 582-590			5
118	Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid. <i>Current Oncology Reports,</i> <b>2019,</b> 21, 18	6.3		14
117	Management of cancer-associated venous thromboembolism - a case-based practical approach. <b>2018,</b> 47, 77-89			12

116	Gastrointestinal Malignancies and Venous Thromboembolic Disease: Clinical Significance and Endovascular Interventions. <b>2020</b> , 4, 260-266			1
115	The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis. <b>2020</b> , 105, 360-362			5
114	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <b>2019</b> , 2019, 71-79			6
113	Diagnosis and therapy in cancer-associated thromboembolism [what about guideline recommendations?]. <b>2015</b> , 44, 299-303			1
112	Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants. <b>2020</b> , 26, 2692-2702			0
111	Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials. <b>2020</b> , 16, 2591-2594			1
110	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. <b>2019</b> , 34, e52			8
109	Two perspectives on venous thromboembolism in oncology. <i>Vnitřni Lekarství</i> , <b>2017</b> , 63, 431-440	0.3		1
108	Venous thromboembolism in cancer patients: Still looking for answers. <b>2019</b> , 18, 5026-5032			19
107	Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. <b>2019</b> , 34, 1125-1135			10
106	Mildly Elevated Cardiac Troponin below the 99th-Percentile Upper Reference Limit after Noncardiac Surgery. <b>2020</b> , 50, 925-937			3
105	Rivaroxaban: Drug review. <i>Cancer Research Statistics and Treatment</i> , <b>2020</b> , 3, 264	0.3		2
104	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. <b>2019</b> , 11, 866-876			8
103	. <b>2017</b> , 109, 1-76			119
102	Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. <b>2016</b> , 32, 1-22			22
101	Risk of Venous Thromboembolism in Glioblastoma Patients. <i>Cureus</i> , <b>2018</b> , 10, e2678	1.2		4
100	Risk assessment for recurrent venous thromboembolism in patients with cancer. <b>2021</b> , 5, 100080			2
99	Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. <b>2021</b> , 11, 724682			0

- 98 Survival in patients with cancer-associated thrombosis in relation to anticoagulants: Re-vitalization of warfarin?. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2677-2679 15.4
- 97 Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. **2021**, 1 1
- 96 The Incidence of Cancer Associated Thrombosis is Increasing Over Time. **2021**, 1 1
- 95 Venous Thromboembolism for the Practicing Cardiologist. **2021**, 39, 551-566 0
- 94 Low molecular heparin for cancer-associated venous thromboembolism [Still the [MATCH of the day]. **2015**, 44, 256-260
- 93 Bleeding and Thrombosis in a Cancer Patient. **2016**, 395-402
- 92 . **2018**, 107, 145-151
- 91 Thromboembolism and Bleeding. **2018**, 1-20
- 90 An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". **2018**, 93, E225-E227
- 89 Venous Thromboembolism. **2019**, 141-150
- 88 Gastrointestinal Cancers and Thrombosis. **2019**, 367-378
- 87 Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer. **2019**, 153, 122-125 0
- 86 Cancer-Associated Thrombosis (CAT). **2020**, 127-145
- 85 Anticoagulants oraux directs dans la maladie thromboembolique veineuse associ e aux cancers. **2020**, 2020, 2-8
- 84 Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer. **2020**, 47-54
- 83 Revisi n sistem tica y metan lisis del tratamiento anticoagulante en la trombosis asociada al c ncer. Implicaciones en estudios de no inferioridad. **2020**, 61, 165-180
- 82 Anticoagulation treatment of cancer patients with deep or superficial leg vein thrombosis - a retrospective observational study of German statutory health insurance claims data (the CERTIFICAT initiative). **2020**, 49, 403-409 0
- 81 The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines. **2021**, 19, 76 2

80	CURRENT VIEW ON ANTICOAGULANT AND THROMBOLYTIC TREATMENT OF ACUTE PULMONARY EMBOLISM. <b>2019</b> , 9, 348-366		
79	[Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?]. <i>Bulletin Du Cancer</i> , <b>2020</b> , 107, 224-233	2.4	
78	Risk of Cancer-Associated Thrombosis and Bleeding in Veterans With Malignancy Who Are Receiving Direct Oral Anticoagulants. <b>2018</b> , 35, S28-S34		
77	Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates. <b>2020</b> , 36, 562-582		4
76	Gerinnung. <b>2022</b> , 77-83		
75	The impact of warfarin on overall survival in cancer patients. <i>Thrombosis Research</i> , <b>2021</b> ,	8.2	
74	Recurrence of Cancer-associated Venous Thromboembolism between 2009 and 2013: A Nationwide Korean Study. <i>Clinical &amp; Experimental Thrombosis and Hemostasis</i> , <b>2021</b> , 7, 14-19	0	1
73	Intraoperative Hyperglycemia May Be Associated with an Increased Risk of Myocardial Injury after Non-Cardiac Surgery in Diabetic Patients. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	
72	Anticoagulants in the Management of Pulmonary Embolism.		0
71	Cancer-Associated Thrombosis - Patient-Reported Outcomes With Rivaroxaban (COSIMO) - Baseline characteristics and clinical outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12604	5.1	0
70	Comparison of Chemical and Mechanical Prophylaxis of Venous Thromboembolism in Non-surgical Mechanically Ventilated Patients.. <i>Cureus</i> , <b>2021</b> , 13, e19548	1.2	
69	Malignomassoziierte venöse Thromboembolie. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-11	0	
68	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.. <i>Haematologica</i> , 0-0	6.6	3
67	National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society.. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 29, 562-576	0.5	
66	Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.. <i>International Journal of Hematology</i> , <b>2022</b> , 1	2.3	0
65	Practical Treatment Guidance for Cancer-Associated Thrombosis - Managing the Challenging Patient: A Consensus Statement.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 103599	7	2
64	[Treatment of cancer associated thrombosis].. <i>Bulletin Du Cancer</i> , <b>2022</b> ,	2.4	0
63	A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.. <i>Cancers</i> , <b>2022</b> ,	6.6	3

62	A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal.. <i>Blood Coagulation and Fibrinolysis</i> , <b>2022</b> ,	1	0
61	Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population.. <i>Current Oncology Reports</i> , <b>2022</b> , 24, 351	6.3	0
60	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism.. <i>Trends in Cardiovascular Medicine</i> , <b>2022</b> ,	6.9	1
59	Anticoagulation Therapy in Cancer Patients with Thrombosis in the Outpatient Sector of Germany (The CERTIFICAT Initiative)-German Practice of Anticoagulation Therapy of Cancer Patients with Thrombosis. <i>Hamostaseologie</i> , <b>2021</b> ,	1.9	0
58	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective.. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2022</b> , 28, 10760296221082988 <sup>3-3</sup>	3.3	2
57	Anticoagulation for atrial fibrillation in active cancer.. <i>Oncology Letters</i> , <b>2022</b> , 23, 124	2.6	0
56	Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors.. <i>Thrombosis and Haemostasis</i> , <b>2022</b> ,	7	0
55	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.. <i>European Journal of Cancer</i> , <b>2022</b> , 165, 136-145	7.5	1
54	An observational study of intermediate or high dose thromboprophylaxis for critically ill COVID-19 patients. <i>Acta Anaesthesiologica Scandinavica</i> , <b>2021</b> ,	1.9	0
53	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus.. <i>Current Oncology</i> , <b>2021</b> , 28, 5434-5451	2.8	4
52	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , <b>2021</b> , 12, CD006649	5.2	0
51	Cancer thrombosis: Narrative review. <i>Cancer Research Statistics and Treatment</i> , <b>2020</b> , 3, 501	0.3	1
50	Treatment of Cancer-Associated Venous thrombosis with Direct Oral Anticoagulants. <b>2020</b> , 100-114		
49	Image_1.tif. <b>2019</b> ,		
48	Image_2.tif. <b>2019</b> ,		
47	Image_3.tif. <b>2019</b> ,		
46	Image_4.tif. <b>2019</b> ,		
45	Image_5.tif. <b>2019</b> ,		

44	Image_6.tif. <b>2019</b> ,		
43	Venous Thromboembolism In Cancer Patients: "From Evidence to Care".. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2022</b> , 28, 10760296221098717	3.3	
42	Challenging issues in the management of cancer-associated venous thromboembolism.. <i>Blood Research</i> , <b>2022</b> , 57, 44-48	1.4	
41	Platelet transfusion and anticoagulation in haematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multi-centre prospective cohort.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	0
40	Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. <i>Flebologiya</i> , <b>2022</b> , 16, 156	0.4	
39	Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. <i>JMV-Journal De Medecine Vasculaire</i> , <b>2022</b> ,	0.6	
38	The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer. <i>Thrombosis Research</i> , <b>2022</b> , 213, S120-S126	8.2	
37	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , <b>2022</b> , 213, S66-S71	8.2	1
36	Thromboembolic disease treatment during cancer therapy. <b>2023</b> , 162-174		
35	Venous thromboembolism and Cancer. <b>2022</b> , 439-466		
34	Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. <i>Journal of Medical Economics</i> , <b>2022</b> , 25, 840-847	2.4	0
33	Prevention and treatment of cancer associated venous thromboembolism - interdisciplinary consensus. <i>Vnitřni Lekarství</i> , <b>2022</b> , 68, 221-226	0.3	
32	Treatment and bleeding complications of cancer-associated venous thromboembolism: A Korean population-based study. <i>Thrombosis and Haemostasis</i> ,	7	1
31	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. <i>HemaSphere</i> , <b>2022</b> , 6, e750	0.3	0
30	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , <b>2022</b> , 23, e334-e347	21.7	7
29	Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review. <i>International Journal of Clinical Practice</i> , <b>2022</b> , 2022, 1-8	2.9	0
28	Tinzaparin review of its molecular profile, pharmacology, special properties, and clinical uses. <i>European Journal of Clinical Pharmacology</i> ,	2.8	
27	New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism. Volume 16, 2497-2507		0

26	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).	4
25	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).	39
24	Cancer and stroke: What do we know and where do we go?. <b>2022</b> , 219, 133-140	0
23	Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation. <b>2022</b> , 100121	0
22	Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. <b>2022</b> , 101, e29429	0
21	The Impact of Winter Months on Venous Thromboembolism (VTE) Patients: A Retrospective Analysis of Hospital Outcomes in the United States. <b>2022</b> ,	0
20	Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism.	0
19	Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner. <b>2022</b> , 29, 6419-6432	0
18	Venous Thromboembolism in Women with Cancer with an Additional Focus on Breast and Gynecological Cancers. <b>2022</b> , 42, 309-319	0
17	Coagulation Complications of Cancer Patients. 1-8	0
16	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. Volume 18, 793-807	0
15	Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients and Clinicians Awareness. <b>2022</b> , 12, 1594	0
14	Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.	0
13	Direct oral anticoagulants in prevention and treatment of cancer-associated thrombosis. <b>2022</b> , 1, 105-112	0
12	The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study. <b>2023</b> , 07, e14-e29	0
11	Bleeding Risk in Elderly Patients with Venous Thromboembolism Who Would Have Been Excluded from Anticoagulation Trials.	0
10	Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. 030089162211468	0
9	Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment.	0

- 8 Potential clinical benefits of warfarin in end-stage cancers: A retrospective analysis. **2023**, 6, ○
- 7 Prediction model for myocardial injury after non-cardiac surgery using machine learning. **2023**, 13, ○
- 6 Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers. **2023**, 53, 131-135 ○
- 5 Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. **2023**, 16, 131-140 ○
- 4 Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism. **2023**, 21, ○
- 3 Characteristics of stroke after liver and kidney transplantation. 14, ○
- 2 An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism. **2023**, 25, 425-432 ○
- 1 Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges. **2023**, 24, 693-710 ○